The NFL will spend up to $1 million funding up to five studies that will examine how to better help players ease their pain and find alternatives to opioids.
Among those potential alternatives: marijuana and other cannabis-derived products.
The league announced its call for research proposals Tuesday. The league and the NFL Players Association formed a joint pain management committee in 2019 to help find alternatives to opioids and give players and league medical staffs information on pain management.
Dr. Allen Sills, the NFL's chief medical officer, said there are a lot of great ideas and important research that need to be funded.
“This is really not an NFL issue or a sports issue,” Sills said. "This is a societal issue, which is how can we better understand and treat pain and what are the alternatives that may be out there for treatment in addition to opioids which have long been used.”
Some retired NFL players, including Nate Jackson and Kyle Turley, have spoken out about their use of marijuana during their time in the league and said it's a better way of managing pain than the drugs prescribed by team doctors. The league prohibits marijuana use by players.
Jeff Miller, the NFL’s executive vice president overseeing player health and safety, said the league’s policy on substance abuse is not changing, with Tuesday’s announcement focused only on proposals and research.
The pain management committee held two forums in 2020 to learn more about cannabidiol science and manufacturing and now wants more information on how cannabinoids not only affect pain but the performance of NFL players.
Dr. Kevin Hill is co-chairman of the joint pain management committee and wrote a book titled “Marijuana: The Unbiased Truth about the World's Most Popular Weed." He said players have been asking about cannabis and cannabidiol CBD. Hill said they've tried to provide the best information on a controversial topic.
“Unfortunately, the level of interest right now far exceeds the level of evidence supporting the use of medical cannabis for pain,” Hill said.
Hill, also director of addiction psychiatry at Beth Israel Deaconess Medical Center and associate professor of psychiatry at Harvard Medical School, said there are flaws in each of the controlled trials despite some evidence supporting the use of medical cannabis for pain.
“That’s why we put out this request for proposals so that we can collectively with the PA, the players association, move towards finding better treatments for pain. Those treatments may include cannabis, and they may include CBD,” Hill said.
The NFL opened the application process Tuesday. The league wants initial proposals studying how cannabinoids can help players manage pain daily and after surgery, how cannabis or cannabinoids affect players' athletic performance, and how other non-pharmaceutical treatments can benefit players.
Proposals must be submitted by July 31 with the pain management committee paring down submissions for formal presentations. Those will presented in November with a final decision the week of Dec. 6.
Jill and Carlo cover the news out of Facebook's latest earnings, Tesla's monumental day, Dave Chappelle addresses controversy and the tragedy of the climate emergency.
The UN's World Meteorological Organization reported that carbon dioxide in the atmosphere hit record levels in 2020, despite coronavirus-related lockdowns. With the COP26 international meeting on climate change less than a week away, Risk and behavioral scientist Dr. Sweta Chakraborty joined Cheddar to break down the "code red for humanity" the report represents and what actual commitments must be made to prevent significant global temperature increases.
The United Nations COP26 climate talks are scheduled for October 31 to November 12 in Glasgow, Scotland. Heads of state will be joined by private sector leaders to once again discuss the shrinking window of time left to take action against global temperature rise. Barbara Humpton, CEO of focused technology company Siemens U.S., is also attending and spoke to Cheddar about what she hopes to see during the conference for both the public and private spheres. "What we are really urging is that there are large commitments made in Glasgow and that we really commit to this next decade of action," she said.
Voyager, Nanoracks, and Lockheed Martin are all teaming up to develop the first-ever free-flying commercial space station with room for a crew of four astronauts. The private companies are joining forces as part of NASA’s greater mission to retire the International Space Station by the year 2030. The low-earth orbit space station will be called "Starlab," and is planned to achieve operational capability by 2027. Lisa Callahan, Vice President and General Manager of Commercial Civil Space at Lockheed Martin, and Matthew J. Kuta, President and Chief Operating Officer of Voyager Space, joined Cheddar’s Opening Bell.
Jill and Carlo cover the latest developments in the Alec Baldwin prop gun shooting, when vaccines for kids as young as 5 should be approved, new reporting on Facebook and more.
Middle school students from across the country battled it out for a chance at being crowned 'America's Top Scientist.' Each applicant had to submit a video to compete in the '3M Young Scientist Challenge' and describe a unique solution to an everyday problem for the chance to win $25,000. 10 finalists were chosen and after a two-day virtual competition, one walked away with the title. 14-year-old Sarah Park won the award, she joins Cheddar News to talk about her invention Spark Care+.
NIAID Director Dr. Anthony Fauci has stated that recipients of the single-dose Johnson & Johnson COVID-19 vaccine should have gotten two doses, to begin with. An FDA panel had recently recommended that J&J boosters be made available for everyone who received the single dose.
Richard Branson’s Virgin Galactic is delaying its launch date for commercial space flights to Q4 of 2022 following a rescheduled test flight. Shares for the aerospace company fell on the news.
The NIH released findings of a study that say recipients of the Johnson & Johnson COVID-19 vaccine may benefit from getting Pfizer or Moderna boosters as the antibody levels from those shots were seen as more robust than from a Johnson & Johnson booster.
